Cargando…
Acinetobacter baumannii Infections in Hospitalized Patients, Treatment Outcomes
Background Acinetobacter baumannii (AB), an opportunistic pathogen, could develop into serious infections with high mortality and financial burden. The debate surrounding the selection of effective antibiotic treatment necessitates studies to define the optimal approach. This study aims to compare t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229601/ https://www.ncbi.nlm.nih.gov/pubmed/34070398 http://dx.doi.org/10.3390/antibiotics10060630 |
_version_ | 1783713016081022976 |
---|---|
author | Alrahmany, Diaa Omar, Ahmed F. Harb, Gehan El Nekidy, Wasim S. Ghazi, Islam M. |
author_facet | Alrahmany, Diaa Omar, Ahmed F. Harb, Gehan El Nekidy, Wasim S. Ghazi, Islam M. |
author_sort | Alrahmany, Diaa |
collection | PubMed |
description | Background Acinetobacter baumannii (AB), an opportunistic pathogen, could develop into serious infections with high mortality and financial burden. The debate surrounding the selection of effective antibiotic treatment necessitates studies to define the optimal approach. This study aims to compare the clinical outcomes of commonly used treatment regimens in hospitalized patients with AB infections to guide stewardship efforts. Material and methods: Ethical approval was obtained, 320 adult patients with confirmed AB infections admitted to our tertiary care facility within two years were enrolled. The treatment outcomes were statistically analyzed to study the relation between antibiotic regimens and 14, 28, and 90-day mortality as the primary outcomes using binary logistic regression—using R software—in addition to the length of hospitalization, adverse events due to antibiotic treatment, and 90-day recurrence as secondary outcomes. Results: Among 320 patients, 142 (44%) had respiratory tract, 105 (33%) soft tissue, 42 (13%) urinary tract, 22 (7%) bacte iemia, and other infections 9 (3%). Nosocomial infections were 190 (59%) versus community-acquired. Monotherapy was significantly associated with lower 28-day (p < 0.05, OR:0.6] and 90-day (p < 0.05, OR:0.4) mortality rates, shorter length of stay LOS (p < 0.05, Median: −12 days] and limited development of adverse events (p < 0.05, OR:0.4). Subgroup analysis revealed similar results ranging from lower odds of mortality, adverse events, and shorter LOS to statistically significant correlation to monotherapy. Meropenem (MEM) and piperacillin/tazobactam (PIP/TAZ) monotherapies showed non-significant high odd ratios of mortalities, adverse events, and disparate LOS. There was a statistical correlation between most combined therapies and adverse events, and longer LOS. Colistin based and colistin/meropenem (CST/MEM) combinations were superior in terms of 14-day mortality (p = 0.05, OR:0.4) and (p < 0.05, OR:0.4) respectively. Pip/Taz and MEM-based combined therapies were associated with statistically non-significant high odd ratios of mortalities. Tigecycline (TGC)-based combinations showed a significant correlation to mortalities (p < 0.05, OR:2.5). Conclusion: Monotherapy was associated with lower mortality rates, shorter LOS, and limited development of adverse events compared to combined therapies. Colistin monotherapy, colistin/meropenem, and other colistin combinations showed almost equivalent mortality outcomes. Patients on combined therapy were more susceptible to adverse events and comparable LOS. The possible adverse outcomes of PIP/TAZ and MEM-based therapies in the treatment of MDRAB infections and the association of TGC with a higher mortality rate raise doubts about their treatment role. |
format | Online Article Text |
id | pubmed-8229601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82296012021-06-26 Acinetobacter baumannii Infections in Hospitalized Patients, Treatment Outcomes Alrahmany, Diaa Omar, Ahmed F. Harb, Gehan El Nekidy, Wasim S. Ghazi, Islam M. Antibiotics (Basel) Article Background Acinetobacter baumannii (AB), an opportunistic pathogen, could develop into serious infections with high mortality and financial burden. The debate surrounding the selection of effective antibiotic treatment necessitates studies to define the optimal approach. This study aims to compare the clinical outcomes of commonly used treatment regimens in hospitalized patients with AB infections to guide stewardship efforts. Material and methods: Ethical approval was obtained, 320 adult patients with confirmed AB infections admitted to our tertiary care facility within two years were enrolled. The treatment outcomes were statistically analyzed to study the relation between antibiotic regimens and 14, 28, and 90-day mortality as the primary outcomes using binary logistic regression—using R software—in addition to the length of hospitalization, adverse events due to antibiotic treatment, and 90-day recurrence as secondary outcomes. Results: Among 320 patients, 142 (44%) had respiratory tract, 105 (33%) soft tissue, 42 (13%) urinary tract, 22 (7%) bacte iemia, and other infections 9 (3%). Nosocomial infections were 190 (59%) versus community-acquired. Monotherapy was significantly associated with lower 28-day (p < 0.05, OR:0.6] and 90-day (p < 0.05, OR:0.4) mortality rates, shorter length of stay LOS (p < 0.05, Median: −12 days] and limited development of adverse events (p < 0.05, OR:0.4). Subgroup analysis revealed similar results ranging from lower odds of mortality, adverse events, and shorter LOS to statistically significant correlation to monotherapy. Meropenem (MEM) and piperacillin/tazobactam (PIP/TAZ) monotherapies showed non-significant high odd ratios of mortalities, adverse events, and disparate LOS. There was a statistical correlation between most combined therapies and adverse events, and longer LOS. Colistin based and colistin/meropenem (CST/MEM) combinations were superior in terms of 14-day mortality (p = 0.05, OR:0.4) and (p < 0.05, OR:0.4) respectively. Pip/Taz and MEM-based combined therapies were associated with statistically non-significant high odd ratios of mortalities. Tigecycline (TGC)-based combinations showed a significant correlation to mortalities (p < 0.05, OR:2.5). Conclusion: Monotherapy was associated with lower mortality rates, shorter LOS, and limited development of adverse events compared to combined therapies. Colistin monotherapy, colistin/meropenem, and other colistin combinations showed almost equivalent mortality outcomes. Patients on combined therapy were more susceptible to adverse events and comparable LOS. The possible adverse outcomes of PIP/TAZ and MEM-based therapies in the treatment of MDRAB infections and the association of TGC with a higher mortality rate raise doubts about their treatment role. MDPI 2021-05-25 /pmc/articles/PMC8229601/ /pubmed/34070398 http://dx.doi.org/10.3390/antibiotics10060630 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Alrahmany, Diaa Omar, Ahmed F. Harb, Gehan El Nekidy, Wasim S. Ghazi, Islam M. Acinetobacter baumannii Infections in Hospitalized Patients, Treatment Outcomes |
title | Acinetobacter baumannii Infections in Hospitalized Patients, Treatment Outcomes |
title_full | Acinetobacter baumannii Infections in Hospitalized Patients, Treatment Outcomes |
title_fullStr | Acinetobacter baumannii Infections in Hospitalized Patients, Treatment Outcomes |
title_full_unstemmed | Acinetobacter baumannii Infections in Hospitalized Patients, Treatment Outcomes |
title_short | Acinetobacter baumannii Infections in Hospitalized Patients, Treatment Outcomes |
title_sort | acinetobacter baumannii infections in hospitalized patients, treatment outcomes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229601/ https://www.ncbi.nlm.nih.gov/pubmed/34070398 http://dx.doi.org/10.3390/antibiotics10060630 |
work_keys_str_mv | AT alrahmanydiaa acinetobacterbaumanniiinfectionsinhospitalizedpatientstreatmentoutcomes AT omarahmedf acinetobacterbaumanniiinfectionsinhospitalizedpatientstreatmentoutcomes AT harbgehan acinetobacterbaumanniiinfectionsinhospitalizedpatientstreatmentoutcomes AT elnekidywasims acinetobacterbaumanniiinfectionsinhospitalizedpatientstreatmentoutcomes AT ghaziislamm acinetobacterbaumanniiinfectionsinhospitalizedpatientstreatmentoutcomes |